Platform & Strategies
Publications
HomePlatform & StrategiesPublications
| NO | Pipeline | Name | Title | |
|---|---|---|---|---|
| 25 | ABL503 | ASCO2024 | Phase 1 Trial Safety and Efficacy of Ragistomig, a Bispecific Antibody Targeting PD-L1 and 4-1BB in Advanced Solid Tumors |
|
| 24 | ABL503 | SITC 2023 | ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade |
|
| 23 | ABL105 | AACR 2024 | The HER2/4-1BB bispecific antibody, YH32367 (ABL105) demonstrates optimal efficacy and safety for HER2-expressing tumors and exhibits synergistic efficacy when combined with anti-PD-1 antibody |
|
| 22 | ABL407 | AACR2024 | ABL407, a LILRB4x4-1BB Bispecific Antibody with a Wild Type Fc, Exhibits Potent Antitumor Activity by Modulating Immune System in Multiple Ways Involving T cells, Myeloids, and Regulatory T cells |
|
| 21 | ABL112 | AACR2024 | A Novel TIGIT and 4-1BB Bispecific Antibody, ABL112, Exhibits Potent in vitroand in vivo Antitumor Activity Through Dual Immune Modulation |
|
| 20 | ABL103 | PEGS Europe 2023 | PEGS Europe 2023 / ABL103, a novel B7-H4x4-1BB bispecific antibody, exerts potent antitumor activity and good safety profile via B7-H4-dependent 4-1BB activation with increased immune cell infiltration in tumor microenvironment |
|
| 19 | ABL102 | PEGS Europe 2023 | PEGS Europe 2023 / ROR1 targeted 4-1BB conditional bispecific antibody, ABL102, exhibits potent in vitro and in vivo antitumor activity and superior safety profile |
|
| 18 | Neuroscience | CVB2023 | CVB2023 / Grabody B, an IGF1 receptor based shuttle, mediates efficient delivery of biologics across the blood brain barrier |
|
| 17 | ABL102 | AACR2023 | AACR2023 / ROR1 Targeted 4-1BB Stimulatory Bispecific Antibody, ABL102, Exhibits Potent in vitro and in vivo Antitumor Activity and Superior Safety Profile |
|
| 16 | ABL205 | AACR2023 | AACR2023 / Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronideprotected pyrrolobenzodiazepine payload |
|
-
Phase 1 Trial Safety and Efficacy of Ragistomig, a Bispecific Antibody Targeting PD-L1 and 4-1BB in Advanced Solid Tumors
-
ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade
-
The HER2/4-1BB bispecific antibody, YH32367 (ABL105) demonstrates optimal efficacy and safety for HER2-expressing tumors and exhibits synergistic efficacy when combined with anti-PD-1 antibody
-
ABL407, a LILRB4x4-1BB Bispecific Antibody with a Wild Type Fc, Exhibits Potent Antitumor Activity by Modulating Immune System in Multiple Ways Involving T cells, Myeloids, and Regulatory T cells
-
A Novel TIGIT and 4-1BB Bispecific Antibody, ABL112, Exhibits Potent in vitroand in vivo Antitumor Activity Through Dual Immune Modulation
-
PEGS Europe 2023 / ABL103, a novel B7-H4x4-1BB bispecific antibody, exerts potent antitumor activity and good safety profile via B7-H4-dependent 4-1BB activation with increased immune cell infiltration in tumor microenvironment
-
PEGS Europe 2023 / ROR1 targeted 4-1BB conditional bispecific antibody, ABL102, exhibits potent in vitro and in vivo antitumor activity and superior safety profile
-
CVB2023 / Grabody B, an IGF1 receptor based shuttle, mediates efficient delivery of biologics across the blood brain barrier
-
AACR2023 / ROR1 Targeted 4-1BB Stimulatory Bispecific Antibody, ABL102, Exhibits Potent in vitro and in vivo Antitumor Activity and Superior Safety Profile
-
AACR2023 / Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronideprotected pyrrolobenzodiazepine payload